Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

SGYP 4.01 -0.10 (-2.43%)
price chart
Cantor Reiterates Buy on Synergy Pharmaceuticals Inc Following 4Q:14 Update
Cantor analyst Irina Rivkind came out with a research note on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), after the company released its fourth-quarter results, posting a net loss of $30.6M and loss per share of ($0.32), coming in below the FactSet ...
Why Synergy Pharmaceuticals, Inc. Is Surging Higher Today.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Synergy Pharma exploring sale: Bloomberg  Reuters UK
Synergy Pharmaceuticals: Don't Be An April Fool (SGYP)
Synergy Pharmaceuticals is up 59.31% since the publication of my article. Have you taken profits off the table? I have. And I'll tell you why.
Healthcare Stock's Buzzers - Synergy Pharmaceuticals (SGYP), OHR ...  Techsonian (press release)
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10%
Synergy Pharmaceuticals, Inc. (SGYP - Snapshot Report) was a big mover last session, as the company saw its shares rise 10% on the day.
Related articles »  
Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of ...
Related articles »  
Synergy Pharmaceuticals Inc. Announces Issuance of $200 Million of 7.50 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the closing of its previously announced private offering of $200 million ...
Related articles »  
Stock Insights on Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) was among the biggest gainers on the Russell 2000 as the stock popped 9.93% to $3.32, representing a gain of $0.3 per share.
Green-Zone Stocks to Track - Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP ...
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), with shares inclined 3.11%, closed at $4.15. Juno Therapeutics Inc. (NASDAQ:JUNO),with shares jumped 3.10%, settled at $61.53, hitting new 52-week high of $62.50.
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) will be presenting at investment ...
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases.
Synergy Pharmaceuticals Reports 2014 Fourth Quarter and Full-Year Financial ...  Business Wire (press release)
Synergy Pharmaceuticals (SGYP) Issues Earnings Results, Misses Expectations ...  The Legacy
Trending Stocks Analysis In The Spotlight: Synergy Pharmaceuticals Inc ...
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases.